Protara Therapeutics (TARA) Current Leases (2019 - 2026)

Protara Therapeutics' Current Leases history runs 8 years deep, the most recent figure standing at $1.3 million for Q1 2026.

• In Q1 2026, Current Leases rose 8.03% year-over-year to $1.3 million; the TTM figure through Mar 2026 stood at $1.3 million (up 8.03% YoY), while the FY2025 annual figure was $1.2 million, up 10.5% from the prior year.
• Current Leases was $1.3 million for Q1 2026 at Protara Therapeutics, up from $1.2 million in the prior quarter.
• In the past five years, Current Leases ranged from a high of $1.3 million in Q1 2026 to a low of $870000.0 in Q1 2022.
• Historically, Current Leases has averaged $1.0 million across 5 years, with a median of $1.0 million in 2024.
• Biggest YoY gain for Current Leases was 845.65% in 2022; the steepest drop was 7.14% in 2022.
• A 5-year view of Current Leases shows it stood at $917000.0 in 2022, then increased by 7.2% to $983000.0 in 2023, then rose by 14.34% to $1.1 million in 2024, then gained by 10.5% to $1.2 million in 2025, then increased by 1.77% to $1.3 million in 2026.
• The last three Current Leases figures came in at $1.3 million (Q1 2026), $1.2 million (Q4 2025), and $1.2 million (Q3 2025), per Business Quant data.